InterCure Ltd. INCR INCR INCR, which is doing business as Canndoc, announced on Tuesday its financial and operating results for the third quarter ended September 30, 2022.
"We continued to execute on our international expansion plans building our footprint organically and exploring strategic acquisitions in key markets to meet the solid demand for our high-quality branded products," Alexander Rabinovitch, the company's CEO, said. "We expect 2022 to be another milestone year for InterCure, solidifying our leadership position in the pharmaceutical cannabis market."
Q3 2022 Financial Highlights
- Record revenue of CA$39 million ($29.4 million), representing a 63% growth in the third quarter of 2021 and representing sequential growth of 6%.
- Gross profit totaled CA$17.06 million, compared to $CA9.55 million in the prior year's period.
- The gross profit margin was 44%, compared to 40% in the same quarter of last year.
- Adjusted EBITDA increased 85% year-over-year to CA$9 million, representing 22% of revenues.
- The adjusted EBITDA margin was 22%, compared to 19% in the corresponding quarter of 2021.
- General and administrative expenses totaled $CA5.4 million, while marketing and selling expenses were roughly CA$6.5 million.
Q3 2022 Operational Highlights
- Record of new product launches with more than 10 new GMP SKUs added to the company's portfolio of products during the quarter.
- Expansion of the company's medical cannabis dedicated pharmacy chain to a total of 25 locations as of the end of the third quarter.
- Continued scaling up production cultivation and production of the Southern facility as the region's largest and most advanced facility of its kind.
Price Action
InterCure's shares traded 4.55% lower at $5.25 per share at the time of writing on Tuesday.
Related News
- InterCure Q2 2022 Revenue Grows 119%, What About Profit?
- Clever Leaves To Ship First Export Of Cannabis To Israeli Partner InterCure
- InterCure And Berner's Cookies Launch Flagship Cannabis Pharmacy In Be'er Sheva, Israel
Photo: Courtesy of micheile dot com on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.